QDs conjugated to anti-HER2 were used for immunolabeled breast and lung cancer cells and showed superior performance in a panel of lung cancer cells with differential HER2 expression, suggesting that they may be a useful tool for the identification of cancer biomarkers at an early stage (423). This evidence concerns the gene ERBB2 and lung carcinoma.